SBC vs SSKN

For growth investors, SBC Medical Group Holdings Incorporated (SBC) is the stronger pick with 6.

1% revenue growth year-over-year, versus 0. 6% for STRATA Skin Sciences, Inc. (SSKN). SBC Medical Group Holdings Incorporated (SBC) offers the better valuation at 6. 7x trailing P/E (7. 1x forward), making it the more compelling value choice. Analysts rate SBC Medical Group Holdings Incorporated (SBC) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, SBC Medical Group Holdings Incorporated (SBC) delivered a total return of -67.

7%, compared to -99. 2% for STRATA Skin Sciences, Inc. (SSKN). Over 10 years, the gap is even starker: SBC returned -67. 8% versus SSKN's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), STRATA Skin Sciences, Inc.

(SSKN) is the lower-risk stock at -0. 24β versus SBC Medical Group Holdings Incorporated's 0. 76β — meaning SBC is approximately -411% more volatile than SSKN relative to the S&P 500. On balance sheet safety, SBC Medical Group Holdings Incorporated (SBC) carries a lower debt/equity ratio of 6% versus 3% for STRATA Skin Sciences, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), SBC Medical Group Holdings Incorporated (SBC) is pulling ahead at 6.

1% versus 0. 6% for STRATA Skin Sciences, Inc. (SSKN). On earnings-per-share growth, the picture is similar: STRATA Skin Sciences, Inc. grew EPS 16. 1% year-over-year, compared to 15. 5% for SBC Medical Group Holdings Incorporated. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

SBC Medical Group Holdings Incorporated (SBC) is the more profitable company, earning 22.

7% net margin versus -30. 1% for STRATA Skin Sciences, Inc. — meaning it keeps 22. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SBC leads at 34. 2% versus -27. 6% for SSKN. At the gross margin level — before operating expenses — SBC leads at 76. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, STRATA Skin Sciences, Inc.

(SSKN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 24)). Both have compounded well over 10 years (SSKN: -99. 6%, SBC: -67. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SBC (Industrials) and SSKN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SBC is a small-cap deep-value stock; SSKN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.